MSKCC researchers have identified a mutation in the androgen receptor that drives resistance to second-generation antiandrogen drugs such as Medivation's Xtandi. The team is testing a lead molecule that overcomes this resistance in mouse models for prostate cancer and is considering running a clinical trial.